IBS-C Drugs-Global Market Status and Trend Report 2013-2023
Report Summary
IBS-C Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on IBS-C Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of IBS-C Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of IBS-C Drugs worldwide, with company and product introduction, position in the IBS-C Drugs market
Market status and development trend of IBS-C Drugs by types and applications
Cost and profit status of IBS-C Drugs, and marketing status
Market growth drivers and challenges
The report segments the global IBS-C Drugs market as:
Global IBS-C Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global IBS-C Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Other
Global IBS-C Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global IBS-C Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, IBS-C Drugs Sales Volume, Revenue, Price and Gross Margin):
Catalent Pharmaceuticals Solutions
Nestle
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Novartis Pharma Ag
Astellas Pharmaceuticals
Ardelyx, Inc
Synthetic Biologics, Inc
Teva Pharmaceutical Industries
Bama-Geve, SLU
Ferring BV
Ironwood Pharmaceuticals, Inc
Salix Pharmaceuticals Ltd
Norgine B.V
Prometheus Laboratories Inc
Actavis Nordic A/S
Albireo Pharma Inc
Yuhan Corp
Astrazeneca Plc
The Menarini Group
Ono Pharmaceutical Co., Ltd
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
IBS-C Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on IBS-C Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Regional Market Size of IBS-C Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of IBS-C Drugs worldwide, with company and product introduction, position in the IBS-C Drugs market
Market status and development trend of IBS-C Drugs by types and applications
Cost and profit status of IBS-C Drugs, and marketing status
Market growth drivers and challenges
The report segments the global IBS-C Drugs market as:
Global IBS-C Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America
Global IBS-C Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Other
Global IBS-C Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global IBS-C Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, IBS-C Drugs Sales Volume, Revenue, Price and Gross Margin):
Catalent Pharmaceuticals Solutions
Nestle
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Novartis Pharma Ag
Astellas Pharmaceuticals
Ardelyx, Inc
Synthetic Biologics, Inc
Teva Pharmaceutical Industries
Bama-Geve, SLU
Ferring BV
Ironwood Pharmaceuticals, Inc
Salix Pharmaceuticals Ltd
Norgine B.V
Prometheus Laboratories Inc
Actavis Nordic A/S
Albireo Pharma Inc
Yuhan Corp
Astrazeneca Plc
The Menarini Group
Ono Pharmaceutical Co., Ltd
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF IBS-C DRUGS
1.1 Definition of IBS-C Drugs in This Report
1.2 Commercial Types of IBS-C Drugs
1.2.1 Linaclotide
1.2.2 Lubiprostone
1.2.3 Osmotic Laxatives
1.2.4 Stimulant Laxatives
1.2.5 Other
1.3 Downstream Application of IBS-C Drugs
1.3.1 Hospital Pharmacies
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.4 Development History of IBS-C Drugs
1.5 Market Status and Trend of IBS-C Drugs 2013-2023
1.5.1 Global IBS-C Drugs Market Status and Trend 2013-2023
1.5.2 Regional IBS-C Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of IBS-C Drugs 2013-2017
2.2 Sales Market of IBS-C Drugs by Regions
2.2.1 Sales Volume of IBS-C Drugs by Regions
2.2.2 Sales Value of IBS-C Drugs by Regions
2.3 Production Market of IBS-C Drugs by Regions
2.4 Global Market Forecast of IBS-C Drugs 2018-2023
2.4.1 Global Market Forecast of IBS-C Drugs 2018-2023
2.4.2 Market Forecast of IBS-C Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of IBS-C Drugs by Types
3.2 Sales Value of IBS-C Drugs by Types
3.3 Market Forecast of IBS-C Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of IBS-C Drugs by Downstream Industry
4.2 Global Market Forecast of IBS-C Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America IBS-C Drugs Market Status by Countries
5.1.1 North America IBS-C Drugs Sales by Countries (2013-2017)
5.1.2 North America IBS-C Drugs Revenue by Countries (2013-2017)
5.1.3 United States IBS-C Drugs Market Status (2013-2017)
5.1.4 Canada IBS-C Drugs Market Status (2013-2017)
5.1.5 Mexico IBS-C Drugs Market Status (2013-2017)
5.2 North America IBS-C Drugs Market Status by Manufacturers
5.3 North America IBS-C Drugs Market Status by Type (2013-2017)
5.3.1 North America IBS-C Drugs Sales by Type (2013-2017)
5.3.2 North America IBS-C Drugs Revenue by Type (2013-2017)
5.4 North America IBS-C Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe IBS-C Drugs Market Status by Countries
6.1.1 Europe IBS-C Drugs Sales by Countries (2013-2017)
6.1.2 Europe IBS-C Drugs Revenue by Countries (2013-2017)
6.1.3 Germany IBS-C Drugs Market Status (2013-2017)
6.1.4 UK IBS-C Drugs Market Status (2013-2017)
6.1.5 France IBS-C Drugs Market Status (2013-2017)
6.1.6 Italy IBS-C Drugs Market Status (2013-2017)
6.1.7 Russia IBS-C Drugs Market Status (2013-2017)
6.1.8 Spain IBS-C Drugs Market Status (2013-2017)
6.1.9 Benelux IBS-C Drugs Market Status (2013-2017)
6.2 Europe IBS-C Drugs Market Status by Manufacturers
6.3 Europe IBS-C Drugs Market Status by Type (2013-2017)
6.3.1 Europe IBS-C Drugs Sales by Type (2013-2017)
6.3.2 Europe IBS-C Drugs Revenue by Type (2013-2017)
6.4 Europe IBS-C Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific IBS-C Drugs Market Status by Countries
7.1.1 Asia Pacific IBS-C Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific IBS-C Drugs Revenue by Countries (2013-2017)
7.1.3 China IBS-C Drugs Market Status (2013-2017)
7.1.4 Japan IBS-C Drugs Market Status (2013-2017)
7.1.5 India IBS-C Drugs Market Status (2013-2017)
7.1.6 Southeast Asia IBS-C Drugs Market Status (2013-2017)
7.1.7 Australia IBS-C Drugs Market Status (2013-2017)
7.2 Asia Pacific IBS-C Drugs Market Status by Manufacturers
7.3 Asia Pacific IBS-C Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific IBS-C Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific IBS-C Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific IBS-C Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America IBS-C Drugs Market Status by Countries
8.1.1 Latin America IBS-C Drugs Sales by Countries (2013-2017)
8.1.2 Latin America IBS-C Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil IBS-C Drugs Market Status (2013-2017)
8.1.4 Argentina IBS-C Drugs Market Status (2013-2017)
8.1.5 Colombia IBS-C Drugs Market Status (2013-2017)
8.2 Latin America IBS-C Drugs Market Status by Manufacturers
8.3 Latin America IBS-C Drugs Market Status by Type (2013-2017)
8.3.1 Latin America IBS-C Drugs Sales by Type (2013-2017)
8.3.2 Latin America IBS-C Drugs Revenue by Type (2013-2017)
8.4 Latin America IBS-C Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa IBS-C Drugs Market Status by Countries
9.1.1 Middle East and Africa IBS-C Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa IBS-C Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East IBS-C Drugs Market Status (2013-2017)
9.1.4 Africa IBS-C Drugs Market Status (2013-2017)
9.2 Middle East and Africa IBS-C Drugs Market Status by Manufacturers
9.3 Middle East and Africa IBS-C Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa IBS-C Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa IBS-C Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa IBS-C Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF IBS-C DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 IBS-C Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 IBS-C DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of IBS-C Drugs by Major Manufacturers
11.2 Production Value of IBS-C Drugs by Major Manufacturers
11.3 Basic Information of IBS-C Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of IBS-C Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of IBS-C Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 IBS-C DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Catalent Pharmaceuticals Solutions
12.1.1 Company profile
12.1.2 Representative IBS-C Drugs Product
12.1.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Catalent Pharmaceuticals Solutions
12.2 Nestle
12.2.1 Company profile
12.2.2 Representative IBS-C Drugs Product
12.2.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Nestle
12.3 Abbott Laboratories
12.3.1 Company profile
12.3.2 Representative IBS-C Drugs Product
12.3.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
12.4 Synergy Pharmaceuticals
12.4.1 Company profile
12.4.2 Representative IBS-C Drugs Product
12.4.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Synergy Pharmaceuticals
12.5 Sucampo Pharmaceuticals
12.5.1 Company profile
12.5.2 Representative IBS-C Drugs Product
12.5.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Sucampo Pharmaceuticals
12.6 Novartis Pharma Ag
12.6.1 Company profile
12.6.2 Representative IBS-C Drugs Product
12.6.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Novartis Pharma Ag
12.7 Astellas Pharmaceuticals
12.7.1 Company profile
12.7.2 Representative IBS-C Drugs Product
12.7.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharmaceuticals
12.8 Ardelyx, Inc
12.8.1 Company profile
12.8.2 Representative IBS-C Drugs Product
12.8.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ardelyx, Inc
12.9 Synthetic Biologics, Inc
12.9.1 Company profile
12.9.2 Representative IBS-C Drugs Product
12.9.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Synthetic Biologics, Inc
12.10 Teva Pharmaceutical Industries
12.10.1 Company profile
12.10.2 Representative IBS-C Drugs Product
12.10.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries
12.11 Bama-Geve, SLU
12.11.1 Company profile
12.11.2 Representative IBS-C Drugs Product
12.11.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Bama-Geve, SLU
12.12 Ferring BV
12.12.1 Company profile
12.12.2 Representative IBS-C Drugs Product
12.12.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ferring BV
12.13 Ironwood Pharmaceuticals, Inc
12.13.1 Company profile
12.13.2 Representative IBS-C Drugs Product
12.13.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ironwood Pharmaceuticals, Inc
12.14 Salix Pharmaceuticals Ltd
12.14.1 Company profile
12.14.2 Representative IBS-C Drugs Product
12.14.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Salix Pharmaceuticals Ltd
12.15 Norgine B.V
12.15.1 Company profile
12.15.2 Representative IBS-C Drugs Product
12.15.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Norgine B.V
12.16 Prometheus Laboratories Inc
12.17 Actavis Nordic A/S
12.18 Albireo Pharma Inc
12.19 Yuhan Corp
12.20 Astrazeneca Plc
12.21 The Menarini Group
12.22 Ono Pharmaceutical Co., Ltd
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IBS-C DRUGS
13.1 Industry Chain of IBS-C Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF IBS-C DRUGS
14.1 Cost Structure Analysis of IBS-C Drugs
14.2 Raw Materials Cost Analysis of IBS-C Drugs
14.3 Labor Cost Analysis of IBS-C Drugs
14.4 Manufacturing Expenses Analysis of IBS-C Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of IBS-C Drugs in This Report
1.2 Commercial Types of IBS-C Drugs
1.2.1 Linaclotide
1.2.2 Lubiprostone
1.2.3 Osmotic Laxatives
1.2.4 Stimulant Laxatives
1.2.5 Other
1.3 Downstream Application of IBS-C Drugs
1.3.1 Hospital Pharmacies
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.4 Development History of IBS-C Drugs
1.5 Market Status and Trend of IBS-C Drugs 2013-2023
1.5.1 Global IBS-C Drugs Market Status and Trend 2013-2023
1.5.2 Regional IBS-C Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of IBS-C Drugs 2013-2017
2.2 Sales Market of IBS-C Drugs by Regions
2.2.1 Sales Volume of IBS-C Drugs by Regions
2.2.2 Sales Value of IBS-C Drugs by Regions
2.3 Production Market of IBS-C Drugs by Regions
2.4 Global Market Forecast of IBS-C Drugs 2018-2023
2.4.1 Global Market Forecast of IBS-C Drugs 2018-2023
2.4.2 Market Forecast of IBS-C Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of IBS-C Drugs by Types
3.2 Sales Value of IBS-C Drugs by Types
3.3 Market Forecast of IBS-C Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of IBS-C Drugs by Downstream Industry
4.2 Global Market Forecast of IBS-C Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America IBS-C Drugs Market Status by Countries
5.1.1 North America IBS-C Drugs Sales by Countries (2013-2017)
5.1.2 North America IBS-C Drugs Revenue by Countries (2013-2017)
5.1.3 United States IBS-C Drugs Market Status (2013-2017)
5.1.4 Canada IBS-C Drugs Market Status (2013-2017)
5.1.5 Mexico IBS-C Drugs Market Status (2013-2017)
5.2 North America IBS-C Drugs Market Status by Manufacturers
5.3 North America IBS-C Drugs Market Status by Type (2013-2017)
5.3.1 North America IBS-C Drugs Sales by Type (2013-2017)
5.3.2 North America IBS-C Drugs Revenue by Type (2013-2017)
5.4 North America IBS-C Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe IBS-C Drugs Market Status by Countries
6.1.1 Europe IBS-C Drugs Sales by Countries (2013-2017)
6.1.2 Europe IBS-C Drugs Revenue by Countries (2013-2017)
6.1.3 Germany IBS-C Drugs Market Status (2013-2017)
6.1.4 UK IBS-C Drugs Market Status (2013-2017)
6.1.5 France IBS-C Drugs Market Status (2013-2017)
6.1.6 Italy IBS-C Drugs Market Status (2013-2017)
6.1.7 Russia IBS-C Drugs Market Status (2013-2017)
6.1.8 Spain IBS-C Drugs Market Status (2013-2017)
6.1.9 Benelux IBS-C Drugs Market Status (2013-2017)
6.2 Europe IBS-C Drugs Market Status by Manufacturers
6.3 Europe IBS-C Drugs Market Status by Type (2013-2017)
6.3.1 Europe IBS-C Drugs Sales by Type (2013-2017)
6.3.2 Europe IBS-C Drugs Revenue by Type (2013-2017)
6.4 Europe IBS-C Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific IBS-C Drugs Market Status by Countries
7.1.1 Asia Pacific IBS-C Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific IBS-C Drugs Revenue by Countries (2013-2017)
7.1.3 China IBS-C Drugs Market Status (2013-2017)
7.1.4 Japan IBS-C Drugs Market Status (2013-2017)
7.1.5 India IBS-C Drugs Market Status (2013-2017)
7.1.6 Southeast Asia IBS-C Drugs Market Status (2013-2017)
7.1.7 Australia IBS-C Drugs Market Status (2013-2017)
7.2 Asia Pacific IBS-C Drugs Market Status by Manufacturers
7.3 Asia Pacific IBS-C Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific IBS-C Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific IBS-C Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific IBS-C Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America IBS-C Drugs Market Status by Countries
8.1.1 Latin America IBS-C Drugs Sales by Countries (2013-2017)
8.1.2 Latin America IBS-C Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil IBS-C Drugs Market Status (2013-2017)
8.1.4 Argentina IBS-C Drugs Market Status (2013-2017)
8.1.5 Colombia IBS-C Drugs Market Status (2013-2017)
8.2 Latin America IBS-C Drugs Market Status by Manufacturers
8.3 Latin America IBS-C Drugs Market Status by Type (2013-2017)
8.3.1 Latin America IBS-C Drugs Sales by Type (2013-2017)
8.3.2 Latin America IBS-C Drugs Revenue by Type (2013-2017)
8.4 Latin America IBS-C Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa IBS-C Drugs Market Status by Countries
9.1.1 Middle East and Africa IBS-C Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa IBS-C Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East IBS-C Drugs Market Status (2013-2017)
9.1.4 Africa IBS-C Drugs Market Status (2013-2017)
9.2 Middle East and Africa IBS-C Drugs Market Status by Manufacturers
9.3 Middle East and Africa IBS-C Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa IBS-C Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa IBS-C Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa IBS-C Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF IBS-C DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 IBS-C Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 IBS-C DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of IBS-C Drugs by Major Manufacturers
11.2 Production Value of IBS-C Drugs by Major Manufacturers
11.3 Basic Information of IBS-C Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of IBS-C Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of IBS-C Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 IBS-C DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Catalent Pharmaceuticals Solutions
12.1.1 Company profile
12.1.2 Representative IBS-C Drugs Product
12.1.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Catalent Pharmaceuticals Solutions
12.2 Nestle
12.2.1 Company profile
12.2.2 Representative IBS-C Drugs Product
12.2.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Nestle
12.3 Abbott Laboratories
12.3.1 Company profile
12.3.2 Representative IBS-C Drugs Product
12.3.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
12.4 Synergy Pharmaceuticals
12.4.1 Company profile
12.4.2 Representative IBS-C Drugs Product
12.4.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Synergy Pharmaceuticals
12.5 Sucampo Pharmaceuticals
12.5.1 Company profile
12.5.2 Representative IBS-C Drugs Product
12.5.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Sucampo Pharmaceuticals
12.6 Novartis Pharma Ag
12.6.1 Company profile
12.6.2 Representative IBS-C Drugs Product
12.6.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Novartis Pharma Ag
12.7 Astellas Pharmaceuticals
12.7.1 Company profile
12.7.2 Representative IBS-C Drugs Product
12.7.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharmaceuticals
12.8 Ardelyx, Inc
12.8.1 Company profile
12.8.2 Representative IBS-C Drugs Product
12.8.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ardelyx, Inc
12.9 Synthetic Biologics, Inc
12.9.1 Company profile
12.9.2 Representative IBS-C Drugs Product
12.9.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Synthetic Biologics, Inc
12.10 Teva Pharmaceutical Industries
12.10.1 Company profile
12.10.2 Representative IBS-C Drugs Product
12.10.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries
12.11 Bama-Geve, SLU
12.11.1 Company profile
12.11.2 Representative IBS-C Drugs Product
12.11.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Bama-Geve, SLU
12.12 Ferring BV
12.12.1 Company profile
12.12.2 Representative IBS-C Drugs Product
12.12.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ferring BV
12.13 Ironwood Pharmaceuticals, Inc
12.13.1 Company profile
12.13.2 Representative IBS-C Drugs Product
12.13.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Ironwood Pharmaceuticals, Inc
12.14 Salix Pharmaceuticals Ltd
12.14.1 Company profile
12.14.2 Representative IBS-C Drugs Product
12.14.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Salix Pharmaceuticals Ltd
12.15 Norgine B.V
12.15.1 Company profile
12.15.2 Representative IBS-C Drugs Product
12.15.3 IBS-C Drugs Sales, Revenue, Price and Gross Margin of Norgine B.V
12.16 Prometheus Laboratories Inc
12.17 Actavis Nordic A/S
12.18 Albireo Pharma Inc
12.19 Yuhan Corp
12.20 Astrazeneca Plc
12.21 The Menarini Group
12.22 Ono Pharmaceutical Co., Ltd
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IBS-C DRUGS
13.1 Industry Chain of IBS-C Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF IBS-C DRUGS
14.1 Cost Structure Analysis of IBS-C Drugs
14.2 Raw Materials Cost Analysis of IBS-C Drugs
14.3 Labor Cost Analysis of IBS-C Drugs
14.4 Manufacturing Expenses Analysis of IBS-C Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
